JAZZ Q3 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$972M+3.3% YoY

Gross Profit

$870M89.5% margin

Operating Income

$172M17.7% margin

Net Income

$147M15.1% margin

EPS (Diluted)

$2.14

QoQ Revenue Growth

+1.5%

Cash Flow

Operating Cash Flow

$307M

Free Cash Flow

$303M

Stock-Based Comp.

$56M

Balance Sheet

Total Assets

$11.2B

Total Liabilities

$7.7B

Stockholders' Equity

$3.5B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$972M	$941M	+3.3%
Gross Profit	$870M	$807M	+7.8%
Operating Income	$172M	$25M	+596.2%
Net Income	$147M	-$20M	+847.3%

Revenue Segments

Xywav

$332M34%

Epidiolex/Epidyolex

$214M22%

Xyrem

$125M13%

Rylaze/Enrylaze

$105M11%

Zepzelca

$78M8%

Defitelio/Defibrotide

$48M5%

Vyxeos

$30M3%

High Sodium AG Oxybate Product Royalty Revenue

$29M3%

Other Royalty And Contract Revenues

$5M0%

Sativex

$5M0%

Other Products

$3M0%

Geographic Segments

UNITED STATES

$885M91%

Europe

$69M7%

Other Countries

$19M2%